CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer

BACKGROUND: A phase I/II study and subsequent phase III study (MPACT) reported significant correlations between CA19-9 decreases and prolonged overall survival (OS) with nab-paclitaxel plus gemcitabine (nab-P + Gem) treatment for metastatic pancreatic cancer (MPC). CA19-9 changes at week 8 and poten...

全面介紹

Na minha lista:
書目詳細資料
發表在:Ann Oncol
Main Authors: Chiorean, E. G., Von Hoff, D. D., Reni, M., Arena, F. P., Infante, J. R., Bathini, V. G., Wood, T. E., Mainwaring, P. N., Muldoon, R. T., Clingan, P. R., Kunzmann, V., Ramanathan, R. K., Tabernero, J., Goldstein, D., McGovern, D., Lu, B., Ko, A.
格式: Artigo
語言:Inglês
出版: Oxford University Press 2016
主題:
Original Articles
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4803454/
https://ncbi.nlm.nih.gov/pubmed/26802160
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdw006
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍